NM_000548.5:c.5204T>C

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 2P and 11B. PM1BP4_ModerateBP6BS1BS2

The NM_000548.5(TSC2):​c.5204T>C​(p.Ile1735Thr) variant causes a missense change. The variant allele was found at a frequency of 0.000049 in 1,612,946 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I1735V) has been classified as Likely benign.

Frequency

Genomes: š‘“ 0.00032 ( 1 hom., cov: 34)
Exomes š‘“: 0.000021 ( 0 hom. )

Consequence

TSC2
NM_000548.5 missense

Scores

1
6
12

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:3

Conservation

PhyloP100: 3.92

Publications

2 publications found
Variant links:
Genes affected
TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
TSC2 Gene-Disease associations (from GenCC):
  • tuberous sclerosis
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • tuberous sclerosis 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp, Ambry Genetics
  • lymphangioleiomyomatosis
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • tuberous sclerosis complex
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

PM1
In a hotspot region, there are 5 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 12 benign, 39 uncertain in NM_000548.5
BP4
Computational evidence support a benign effect (MetaRNN=0.08266613).
BP6
Variant 16-2088270-T-C is Benign according to our data. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952. Variant chr16-2088270-T-C is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 661952.
BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.000322 (49/152186) while in subpopulation AMR AF = 0.00321 (49/15286). AF 95% confidence interval is 0.00249. There are 1 homozygotes in GnomAd4. There are 38 alleles in the male GnomAd4 subpopulation. Median coverage is 34. This position passed quality control check.
BS2
High AC in GnomAd4 at 49 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TSC2NM_000548.5 linkc.5204T>C p.Ile1735Thr missense_variant Exon 41 of 42 ENST00000219476.9 NP_000539.2 P49815-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TSC2ENST00000219476.9 linkc.5204T>C p.Ile1735Thr missense_variant Exon 41 of 42 5 NM_000548.5 ENSP00000219476.3 P49815-1

Frequencies

GnomAD3 genomes
AF:
0.000322
AC:
49
AN:
152186
Hom.:
1
Cov.:
34
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00321
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000918
AC:
23
AN:
250616
AF XY:
0.0000737
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000578
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000327
GnomAD4 exome
AF:
0.0000205
AC:
30
AN:
1460760
Hom.:
0
Cov.:
35
AF XY:
0.0000179
AC XY:
13
AN XY:
726650
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33480
American (AMR)
AF:
0.000492
AC:
22
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.0000232
AC:
2
AN:
86258
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
52314
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.00000540
AC:
6
AN:
1111998
Other (OTH)
AF:
0.00
AC:
0
AN:
60382
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.485
Heterozygous variant carriers
0
3
7
10
14
17
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000322
AC:
49
AN:
152186
Hom.:
1
Cov.:
34
AF XY:
0.000511
AC XY:
38
AN XY:
74344
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41442
American (AMR)
AF:
0.00321
AC:
49
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5200
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10624
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68018
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
3
6
8
11
14
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.000230

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:3
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Tuberous sclerosis 2 Uncertain:2Benign:1
Dec 23, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 27, 2019
Baylor Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -

Nov 07, 2021
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

TSC2-related disorder Benign:1
Aug 13, 2024
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Hereditary cancer-predisposing syndrome Benign:1
Sep 28, 2021
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.097
BayesDel_addAF
Benign
-0.0062
T
BayesDel_noAF
Uncertain
0.11
CADD
Benign
18
DANN
Benign
0.80
DEOGEN2
Uncertain
0.55
D;.;.;.;.;.;.;.;.;.;.;.;T;.;T
Eigen
Benign
-0.39
Eigen_PC
Benign
-0.26
FATHMM_MKL
Benign
0.52
D
LIST_S2
Uncertain
0.88
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
0.32
D
MetaRNN
Benign
0.083
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
-0.11
T
MutationAssessor
Benign
1.7
L;.;.;.;.;.;.;.;.;.;.;.;.;.;.
PhyloP100
3.9
PrimateAI
Uncertain
0.54
T
PROVEAN
Benign
-0.57
N;.;.;N;.;N;.;.;N;N;.;.;.;.;N
REVEL
Uncertain
0.58
Sift
Benign
1.0
T;.;.;T;.;T;.;.;T;T;.;.;.;.;T
Sift4G
Benign
0.33
T;.;.;T;.;T;.;.;T;T;.;.;.;.;T
Polyphen
0.0040
B;.;.;.;B;B;.;.;B;B;.;.;.;.;.
Vest4
0.34
MutPred
0.43
Loss of catalytic residue at P1737 (P = 0.0298);.;.;.;.;.;.;.;.;.;.;.;.;.;.;
MVP
0.95
ClinPred
0.049
T
GERP RS
3.1
Varity_R
0.088
gMVP
0.27
Mutation Taster
=87/13
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs786203769; hg19: chr16-2138271; API